A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Alfuzosin (Uroxatral)

alpha-Adrenergic Blocker class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2011-11-22
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$39.8M in CY2024 Part D spend1.7M claims · 588K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.111/unit
9 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.111
Across all dosage forms in distribution.
Highest NADAC
$0.111
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Alfuzosin used for?

Alfuzosin is a alpha-Adrenergic Blocker medication tracked in Medicare Part D.

Is there a generic for Alfuzosin?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Alfuzosin?

Across 329 Part D plans, Alfuzosin averages $0.111/unit (NADAC). Lowest available: $0.111/unit. Highest in distribution: $0.111/unit.

Is Alfuzosin on the FDA shortage list?

No. Alfuzosin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

alpha-Adrenergic Blocker5 alternatives in D1
01
Carvedilol
Brand: Coreg
$0.017Lowest NADAC
12Generic mfrs
$265.2MCY24 Part D spend
Compare →
02
Doxazosin
Brand: Cardura
$0.069Lowest NADAC
9Generic mfrs
$54.9MCY24 Part D spend
Compare →
03
Prazosin
alpha-Adrenergic Blocker
$0.085Lowest NADAC
9Generic mfrs
$37.6MCY24 Part D spend
Compare →
04
Silodosin
Brand: RAPAFLO
$0.272Lowest NADAC
10Generic mfrs
$39.6MCY24 Part D spend
Compare →
05
Terazosin
Brand: TEZRULY
$0.109Lowest NADAC
5Generic mfrs
$42.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (5 approvals on file) · NADAC unit costs: CMS NADAC weekly file (9 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.